ClinicalTrials.gg
TerminatedNCT00191477Updated Oct 28, 2009Results posted

Instillation of Gemcitabine in Patients With Superficial Bladder Cancer

A Phase 3 interventional study of Gemcitabine and Placebo in Bladder Neoplasms, sponsored by Eli Lilly and Company. Terminated at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-10-28.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was stopped early for futility reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
355
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 101 studies testing gemcitabine in Urinary Bladder Neoplasms — 12 open to participants now, 23 under way, 3 of them phase 3. Gemcitabine · Urinary Bladder Neoplasms.

Enrollment
5th of 96
355 · median 42
Started
2004
with 2 others
Phase 3
13 of 101
2 open now
Registered
29th of 101
by date
Lead sponsor
4 of 101
Eli Lilly and Company

Among the 101 studies testing gemcitabine in Urinary Bladder Neoplasms, this one is the 5th largest by enrollment of the 96 interventional ones that give a count, is one of 3 that started in 2004, is one of 13 in phase 3, and was the 29th registered.

Urinary Bladder Neoplasms

1,801 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

12 of the 101 studies testing gemcitabine in Urinary Bladder Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 337 Urinary Bladder Neoplasms studies recruiting now, 257 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies testing gemcitabine in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled Phase 3 multicenter study to assess the efficacy and safety of intravesical instillation of gemcitabine versus placebo immediately after transurethral resection of the bladder tumor.

03

Conditions studied

  • Bladder Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical evidence of superficial transitional cell carcinoma of the bladder
  • Males or females at least 18 years of age
  • Performance Status greater than or equal to 70%
  • Patient compliance and geographic proximity that allow adequate follow-up
  • Female patients with must use a reliable method if appropriate (for example, intrauterine device [IUD], birth control pills, or barrier device) during the study. Female patients with reproductive potential must have a negative serum pregnancy test within 7 days of study enrollment.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Clinical evidence of muscle-invasive or locally advanced bladder cancer
  • Clinical evidence of upper urinary tract tumor
  • Distant
  • Other within the last 2 years, except non-melanotic skin tumors, carcinoma in situ of the cervix or organ-confined prostate cancer after curative therapy
  • Severe concomitant psychiatric disease
  • Febrile, active infection
  • Other serious concomitant disorders that would compromise the safety of the patient or his/her ability to complete the study according to the protocol, at the discretion of the investigator (for example, unstable angina pectoris, uncontrolled diabetes mellitus)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
355 participants (actual)

Study arms

  • Experimental
    A

    Drug: Gemcitabine

  • Placebo comparator
    B

    Drug: Placebo

Interventions

  • 2000 mg, intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)

    Also known as: LY 188011, Gemzar

  • DrugPlacebo

    intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)

06

What researchers measure

Primary outcomes

  1. Recurrence-Free Survival (RFS)

    Defined as the time from study enrollment to the date of the first procedure confirming histopathological recurrence or disease progression or death from any cause. Recurrence-free survival (RFS) was censored at the date of the last follow-up visit for participants who were still alive and who had no recurrence/progression.

    Time frame: Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)

Secondary outcomes

  1. Time to Recurrence

    Time from enrollment to first confirmation of histopathological recurrence or disease progression. Time to recurrence was censored on date of death for patients who died, and on date of last visit for patients who were alive, without recurrence.

    Time frame: Surgery to recurrence (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)

  2. Recurrence-Free Survival (RFS) in Subgroups

    Defined as the time from study enrollment to the date of the first procedure confirming histopathological recurrence or disease progression or death from any cause. Recurrence-free survival was censored at the date of the last follow-up visit for participants who were still alive and who had no recurrence/progression.

    Time frame: Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)

  3. Tumor Recurrence Type

    Tumor recurrence type (superficial, stage pTA or pT1; or muscle-invasive, stage≥pT2) was classified according to American Joint Committee on Cancer Staging Criteria for Bladder Cancer (AJCC Cancer Staging Manual, 6th edition).

    Time frame: Surgery to recurrence (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)

07

Results

Posted Oct 28, 2009
Limitations and caveats
The study was stopped early for futility reasons. In addition, due to limitations in this databank, some original outcome measures are not disclosed. Time to Recurrence and Recurrence-Free Survival in Subgroups had data that were un-estimated.

Participant flow

Participant flow — Overall Study
MilestoneGemcitabinePlacebo
Started179176
Received study drug166162
Completed4147
Not completed138129
Withdrew: Tumor recurrence4948
Withdrew: Death, study disease11
Withdrew: Death, other cause36
Withdrew: Lost to follow-up2321
Withdrew: Protocol violation11
Withdrew: Treatment change20
Withdrew: Withdrawal by subject20
Withdrew: Other20
Withdrew: Not eligible4138
Withdrew: Pathological specimen lost10
Withdrew: Discontinued prior to instillation1314

Outcome measures

PrimaryRecurrence-Free Survival (RFS)

Defined as the time from study enrollment to the date of the first procedure confirming histopathological recurrence or disease progression or death from any cause. Recurrence-free survival (RFS) was censored at the date of the last follow-up visit for participants who were still alive and who had no recurrence/progression.

Time frame:
Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
Reported as:
Median · Months
Recurrence-Free Survival (RFS)
MonthsGemcitabinePlacebo
Recurrence-Free Survival (RFS)37.2 (0.0 to 45.9)40.2 (0.0 to 42.2)
Statistical analysis
  • Gemcitabine vs Placebo · Log Rank · p = 0.777 (Only 87 recurrences and 7 deaths were documented at planned end of follow-up. The study was stopped early for futility reasons based on an interim analysis using pre-defined stopping boundaries for the hazard ratio (HR) of RFS.) · Hazard ratio (hr): 0.946 · 95% CI 0.643 to 1.392
Post-hocPercentage of Participants Without Tumor Recurrence

Because median time to recurrence was not reached, percentage of participants without event was estimated using Kaplan-Meier method. Time to recurrence was censored on date of death for patients who died, and on date of last visit for patients who were alive, without recurrence.

Time frame:
Surgery to recurrence (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
Reported as:
Number · percentage of participants
Percentage of Participants Without Tumor Recurrence
percentage of participantsGemcitabinePlacebo
Recurrence-Free at 12 Months78.4 (56.4 to 74.5)76.9 (53.9 to 71.9)
Recurrence-Free at 24 Months66.363.7
Post-hocPercentage of Participants in Subgroups With Recurrence-Free Survival (RFS) at 12 and 24 Months

RFS rate was estimated using Kaplan-Meier method. RFS was analyzed in different subgroups based on risk, disease status, and concomitant Bacillus Calmette-Guerin (BCG) instillations. Risk: Grading (G1,G2,G3) was performed according to American Joint Committee on Cancer Staging Criteria for Bladder Cancer. Newly diagnosed disease: Initial diagnosis at study entry. Recurrent disease: history of at least one superficial bladder tumor that was surgically treated and relapsed prior to study entry. With BCG: received at least one instillation of BCG during study. Without BCG: didn't receive BCG.

Time frame:
Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
Reported as:
Number · percentage of participants
Percentage of Participants in Subgroups With Recurrence-Free Survival (RFS) at 12 and 24 Months
percentage of participantsGemcitabinePlacebo
Low Risk (G1/G2) - 12 Months (N=106, N=109)78.5 (68.9 to 85.4)78.4 (69.1 to 85.2)
Low Risk (G1/G2) - 24 Months (N=106, N=109)63.964.3
High Risk (G3) - 12 Months (N=13, N=14)66.7 (33.7 to 86.0)42.4 (13.7 to 69.1)
High Risk (G3) - 24 Months (N=13, N=14)57.131.8
Newly Diagnosed Disease - 12 Months (N=94, N=98)79.3 (69.1 to 86.4)79.8 (69.9 to 86.8)
Newly Diagnosed Disease - 24 Months (N=94, N=98)65.463.6
Recurrent Disease - 12 Months (N=30, N=26)72.2 (50.4 to 85.7)58.9 (37.1 to 75.5)
Recurrent Disease - 24 Months (N=30, N=26)59.550.5
With BCG - 12 Months (N=13, N=21)61.5 (30.8 to 81.8)79.4 (54.0 to 91.7)
With BCG - 24 Months (N=13, N=21)49.263.5
Without BCG - 12 Months (N=111, N=103)79.9 (70.6 to 86.6)74.5 (64.4 to 82.1)
Without BCG - 24 Months (N=111, N=103)65.860.1
SecondaryTime to Recurrence

Time from enrollment to first confirmation of histopathological recurrence or disease progression. Time to recurrence was censored on date of death for patients who died, and on date of last visit for patients who were alive, without recurrence.

Time frame:
Surgery to recurrence (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
Reported as:
Median · months

No measurements were reported for this outcome.

SecondaryRecurrence-Free Survival (RFS) in Subgroups

Defined as the time from study enrollment to the date of the first procedure confirming histopathological recurrence or disease progression or death from any cause. Recurrence-free survival was censored at the date of the last follow-up visit for participants who were still alive and who had no recurrence/progression.

Time frame:
Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
Reported as:
Median · months

No measurements were reported for this outcome.

SecondaryTumor Recurrence Type

Tumor recurrence type (superficial, stage pTA or pT1; or muscle-invasive, stage≥pT2) was classified according to American Joint Committee on Cancer Staging Criteria for Bladder Cancer (AJCC Cancer Staging Manual, 6th edition).

Time frame:
Surgery to recurrence (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
Reported as:
Number · participants
Tumor Recurrence Type
participantsGemcitabinePlacebo
No Tumor Recurrence7678
Superficial Tumor - Stage pTa or pT14445
Muscle-Invasive Tumor - Any Stage ≥pT231
pTx - Tumor Cannot be Assessed10

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine—17/166 (10.2%)38/166 (22.9%)
Placebo—10/162 (6.2%)36/162 (22.2%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventGemcitabinePlacebo
Urinary bladder excisionSurgical and medical procedures8/1665/162
Septic shockInfections and infestations0/1661/162
Metastases to lymph nodesNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1661/162
Renal colicRenal and urinary disorders0/1661/162
Urinary bladder haemorrhageRenal and urinary disorders0/1661/162
CystoprostatectomySurgical and medical procedures1/1661/162
Angina pectorisCardiac disorders1/1660/162
Enterovesical fistulaGastrointestinal disorders1/1660/162
Inguinal herniaGastrointestinal disorders1/1660/162
PyelonephritisInfections and infestations1/1660/162
Most frequent other events
Showing 10 of 62
Most frequent other events
EventGemcitabinePlacebo
PainGeneral disorders0/1665/162
CystitisInfections and infestations2/1665/162
Bladder painRenal and urinary disorders5/1663/162
Bladder spasmRenal and urinary disorders1/1664/162
Procedural painInjury, poisoning and procedural complications4/1660/162
Post procedural haemorrhageInjury, poisoning and procedural complications0/1663/162
Sleep disorderPsychiatric disorders1/1663/162
PyrexiaGeneral disorders3/1661/162
HeadacheNervous system disorders3/1660/162
Neck painMusculoskeletal and connective tissue disorders0/1662/162

Baseline characteristics

Age Continuous
Age Continuous(years)GemcitabinePlaceboTotal
Mean63.2 ± 11.966.3 ± 11.064.7 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)GemcitabinePlaceboTotal
Female392665.0
Male127136263.0
Region of Enrollment
Region of Enrollment(participants)GemcitabinePlaceboTotal
Germany131126257.0
Turkey353671.0
Karnofsky Performance Status
Karnofsky Performance Status(participants)GemcitabinePlaceboTotal
70 - Unable to carry on normal activity112.0
80 - Activity with effort; some signs of disease13720.0
90 - Normal activity; minor signs of disease334982.0
100 - Normal no complaints; no evidence of disease118104222.0
Unspecified112.0
Newly Diagnosed versus Recurrent Disease
Newly Diagnosed versus Recurrent Disease(participants)GemcitabinePlaceboTotal
Recurrent Disease434083.0
Newly Diagnosed123122245.0
Race/Ethnicity
Race/Ethnicity(participants)GemcitabinePlaceboTotal
White166162328
Results of Initial Transurethral Resection of a Bladder Tumor (TUR-BT): Number of Visible Lesions
Results of Initial Transurethral Resection of a Bladder Tumor (TUR-BT): Number of Visible Lesions(participants)GemcitabinePlaceboTotal
No Lesions (No Specific Sites Documented)459.0
1 Lesion8796183.0
2 Lesions422769.0
3 Lesions181432.0
4 Lesions71017.0
>=5 Lesions81018.0
Results of Transurethral Resection of Bladder Tumor (TUR-BT): Final Pathological Disease Stage
Results of Transurethral Resection of Bladder Tumor (TUR-BT): Final Pathological Disease Stage(participants)GemcitabinePlaceboTotal
pTx: Primary Tumor Cannot be Assessed303.0
pT0: No Evidence of Primary Tumor000.0
pTa: Noninvasive Papillary Carcinoma9388181.0
pT1: Tumor Invades Subepithelial Connective Tissue313667.0
>=pT2: Tumor Invades Wider Area121022.0
Cis: Carcinoma in situ ("Flat Tumor")5611.0
No Malignancy212243.0
Unspecified101.0

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559,1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physici
    Reinfeld, 23858, Germany
09

References and documents

Publications

  • Han MA, Maisch P, Jung JH, Hwang JE, Narayan V, Cleves A, Hwang EC, Dahm P. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2021 Jun 14;6(6):CD009294. doi: 10.1002/14651858.CD009294.pub3. PubMed 34125951 ↗
  • Bohle A, Leyh H, Frei C, Kuhn M, Tschada R, Pottek T, Wagner W, Knispel HH, von Pokrzywnitzki W, Zorlu F, Helsberg K, Lubben B, Soldatenkova V, Stoffregen C, Buttner H; S274 Study Group. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol. 2009 Sep;56(3):495-503. doi: 10.1016/j.eururo.2009.06.010. Epub 2009 Jun 21. PubMed 19560257 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2004, a primary completion of Mar 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2009, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Jan 2004
Primary completionActual
Mar 2008
CompletionActual
Jun 2008
Results first posted
Oct 28, 2009
Last update
Oct 28, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00191477
First posted
Sep 19, 2005
Start date
Jan 2004
Primary completion
Mar 2008
Completion
Jun 2008
Results posted
Oct 28, 2009
Last update
Oct 28, 2009

Study contacts

Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)
study chair · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion